SCHEMBL4436622

SCHEMBL4436622

CC(C)c1ccc(-c2ccccc2CCl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
DPP4 P27487 1/20 0.38
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
RAB9A P51151 2/20 0.36
PAX8 Q06710 1/20 0.36
NOD2 Q9HC29 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
HTR7 P34969 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9456872 0.84 DPP4 (0.50) KMT2ADPP4PPARGPPARAHTR7
SCHEMBL4432416 0.83 KMT2A (0.47) MAPTKMT2AMEN1USP2LMNA
SCHEMBL31179899 0.82 DPP4 (0.48) KMT2ADPP4PPARGPPARAHTR7
SCHEMBL4437334 0.81 RXRA (0.41) MAPTDPP4ALDH1A1KCNA5KCNH2
SCHEMBL1559894 0.80 CYP2C19 (0.49) KMT2ADPP4SLC6A4SLC6A3RAB9A
SCHEMBL24582843 0.79 SLC6A4 (0.47) MAPTKMT2AMEN1USP2LMNA
SCHEMBL7016124 0.79 HTR7 (0.44) MAPTKMT2AMEN1LMNADPP4
SCHEMBL83911 0.78 DPP4 (0.60) KMT2ADPP4SLC6A2SLC6A4SLC6A3
SCHEMBL1308849 0.76 DPP4 (0.43) KMT2ADPP4PPARGPPARAALDH1A1
SCHEMBL13523298 0.76 CYP2A6 (0.60) MAPTKMT2AMEN1USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 MAPT 4654/4885KMT2A 2978/4885MEN1 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.